Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

DPX-Survivac

- PMLiVE

Corcept Therapeutics reports positive phase 3 results in ovarian cancer treatment

The company also plans to expand its phase 2 BELLA study to include three new study arms

- PMLiVE

BMS acquires Orbital Therapeutics in $1.5bn deal

The deal includes several next-gen cell therapy candidates for autoimmune diseases

- PMLiVE

AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer

Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK

- PMLiVE

Merck shares promising phase 3 results for Keytruda in ovarian cancer

Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type

Approximately 6,000 to 8,000 women in the US are living with low-grade serous ovarian cancer

- PMLiVE

AbbVie’s Elahere shows consistent survival benefits in late-stage ovarian cancer trial

Approximately 20,000 cases of the disease are diagnosed in the US every year

- PMLiVE

NICE recommends pharmaand’s Rubraca for advanced ovarian cancer

An estimated 7,500 new cases of the disease were diagnosed in the UK between 2017 and 2019

- PMLiVE

Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer

Ovarian cancer is the seventh most common cancer in women globally

- PMLiVE

Roche expands cell therapy capabilities with $1.5bn Poseida acquisition

The deal includes a BCMA-targeting allogeneic CAR-T therapy candidate for multiple myeloma

- PMLiVE

AstraZeneca announces $3.5bn US investment to boost research and manufacturing

The commitment is part of the company’s ambition to achieve $80bn in total revenue by 2030

- PMLiVE

Genmab to expand oncology portfolio through $1.8bn ProfoundBio acquisition

The deal includes a next-generation ADC being evaluated as a treatment for ovarian cancer and other solid tumours

- PMLiVE

AbbVie’s Elahere granted full FDA approval for previously-treated ovarian cancer

The company recently gained access to the therapy through its $10.1bn acquisition of ImmunoGen

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links